Margaret Reynolds1, Gregg Lueder2, Mae Gordon3, Robert J Hayashi4. 1. From the Departments of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. Electronic address: Margaret.reynolds@wustl.edu. 2. From the Departments of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA; Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. 3. From the Departments of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. 4. Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Abstract
PURPOSE: The purpose of this study was to describe the academic performance of childhood retinoblastoma (RB) survivors. DESIGN: Retrospective cohort study. METHODS: Retrospective chart review of children followed in a survivorship clinic. RESULTS: A total of 73 patients with RB (median age at diagnosis: 9.97 months; range: 0.29-65.1) were followed for a median of 6.4 years (0.2-1.76). A total of 48 patients (65.8%) had unilateral RB; 43 patients (63.0%) received systemic chemotherapy; and 57 patients (78.1%) underwent enucleation. At last follow-up, 5 children (6.8%) had bilateral visual acuity (VA) <20/70. Seventeen subjects (23.3%) reported school difficulties, and 10 subjects (13.7%) had an individualized education program (IEP). Multivariate analysis revealed that a history of receiving chemotherapy" Multivariate analysis revealed that a history of receiving chemotherapy was associated with self-reported school difficulties (odds ratio [CI]: 5.44; 95% confidence interval [CI]: 1.36-21.69; P = .016), and undergoing an IEP (OR: 11.47; 95% CI: 1.34-98.16; P = .03). The degree of visual impairment and history of enucleation did not influence the risk of self-reported school difficulties or the implementation of an IEP. Among unilateral RB patients, chemotherapy was an independent risk factor for self-reported school difficulties (OR: 12.8; 95% CI: 1.45-113; P = .009) and implementation of an IEP (OR: 15.2; 95% CI: 0.78-292; P = .02). CONCLUSIONS: Academic difficulties in childhood RB survivors are associated with chemotherapy treatment, a risk factor independent of VA.
PURPOSE: The purpose of this study was to describe the academic performance of childhood retinoblastoma (RB) survivors. DESIGN: Retrospective cohort study. METHODS: Retrospective chart review of children followed in a survivorship clinic. RESULTS: A total of 73 patients with RB (median age at diagnosis: 9.97 months; range: 0.29-65.1) were followed for a median of 6.4 years (0.2-1.76). A total of 48 patients (65.8%) had unilateral RB; 43 patients (63.0%) received systemic chemotherapy; and 57 patients (78.1%) underwent enucleation. At last follow-up, 5 children (6.8%) had bilateral visual acuity (VA) <20/70. Seventeen subjects (23.3%) reported school difficulties, and 10 subjects (13.7%) had an individualized education program (IEP). Multivariate analysis revealed that a history of receiving chemotherapy" Multivariate analysis revealed that a history of receiving chemotherapy was associated with self-reported school difficulties (odds ratio [CI]: 5.44; 95% confidence interval [CI]: 1.36-21.69; P = .016), and undergoing an IEP (OR: 11.47; 95% CI: 1.34-98.16; P = .03). The degree of visual impairment and history of enucleation did not influence the risk of self-reported school difficulties or the implementation of an IEP. Among unilateral RB patients, chemotherapy was an independent risk factor for self-reported school difficulties (OR: 12.8; 95% CI: 1.45-113; P = .009) and implementation of an IEP (OR: 15.2; 95% CI: 0.78-292; P = .02). CONCLUSIONS: Academic difficulties in childhood RB survivors are associated with chemotherapy treatment, a risk factor independent of VA.
Authors: Marc H Bornstein; Sara Scrimin; Diane L Putnick; Fabia Capello; O Maurice Haynes; Simona de Falco; Modesto Carli; Marta Pillon Journal: J Pediatr Psychol Date: 2012-02-02
Authors: Guillermo L Chantada; Ibrahim Qaddoumi; Serife Canturk; Vikas Khetan; Zhigui Ma; Kahaki Kimani; Baris Yeniad; Iyad Sultan; Rita S Sitorus; Nurdan Tacyildiz; David H Abramson Journal: Pediatr Blood Cancer Date: 2010-11-11 Impact factor: 3.167
Authors: D L Friedman; B Himelstein; C L Shields; J A Shields; M Needle; D Miller; G R Bunin; A T Meadows Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Helen Dimaras; Kahaki Kimani; Elizabeth A O Dimba; Peggy Gronsdahl; Abby White; Helen S L Chan; Brenda L Gallie Journal: Lancet Date: 2012-03-12 Impact factor: 79.321
Authors: Pauline A Mitby; Leslie L Robison; John A Whitton; Michael A Zevon; Iris C Gibbs; Jean M Tersak; Anna T Meadows; Marilyn Stovall; Lonnie K Zeltzer; Ann C Mertens Journal: Cancer Date: 2003-02-15 Impact factor: 6.921